procainamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Class I antiarrhythmics, procainamide and lidocaine derivatives 2270 51-06-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • procainamide
  • novocainamid
  • novocainamide
  • novocaine amide
  • novocamid
  • procaine amide
  • procanbid
  • procainamide hydrochloride
  • procainamide HCl
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
  • Molecular weight: 235.33
  • Formula: C13H21N3O
  • CLOGP: 1.42
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 58.36
  • ALOGS: -1.89
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 2 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 67 % Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 81 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 212.47 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.84 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 2, 1950 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 94.35 79.71 42 109 456709 34500071

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01BA02 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
ANTIARRHYTHMICS, CLASS I AND III
Antiarrhythmics, class Ia
FDA EPC N0000175426 Antiarrhythmic
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026941 Sodium Channel Blockers
MeSH PA D061567 Voltage-Gated Sodium Channel Blockers
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:38633 sodium channel blockers
CHEBI has role CHEBI:50427 platelet aggregation inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Life-Threatening Ventricular Tachycardia indication
Bundle branch block contraindication 6374002
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Agranulocytosis contraindication 17182001 DOID:12987
Complete atrioventricular block contraindication 27885002
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Second degree atrioventricular block contraindication 195042002
Disease of liver contraindication 235856003 DOID:409
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Myocardial infarction in recovery phase contraindication 418044006
Congenital long QT syndrome contraindication 442917000
Procainamide Toxicity contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.0 acidic
pKa2 8.94 Basic
pKa3 2.36 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel alpha subunit Ion channel BLOCKER CHEMBL CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 7.81 PDSP
Acetylcholinesterase Enzyme Ki 6 WOMBAT-PK
DNA (cytosine-5)-methyltransferase 1 Enzyme WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 3.86 WOMBAT-PK
DNA (cytosine-5)-methyltransferase 3B Enzyme WOMBAT-PK
DNA (cytosine-5)-methyltransferase 3A Enzyme WOMBAT-PK
Acetylcholinesterase Enzyme Ki 6 CHEMBL

External reference:

IDSource
4019904 VUID
N0000147989 NUI
D00477 KEGG_DRUG
614-39-1 SECONDARY_CAS_RN
4017622 VANDF
4019904 VANDF
C0033216 UMLSCUI
CHEBI:8428 CHEBI
CHEMBL640 ChEMBL_ID
DB01035 DRUGBANK_ID
CHEMBL605 ChEMBL_ID
D011342 MESH_DESCRIPTOR_UI
4913 PUBCHEM_CID
4811 IUPHAR_LIGAND_ID
4179 INN_ID
L39WTC366D UNII
155056 RXNORM
5358 MMSL
6415 MMSL
792 MMSL
d00075 MMSL
000622 NDDF
004481 NDDF
11959009 SNOMEDCT_US
25254000 SNOMEDCT_US
372589008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PROCAINAMIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9939 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 12 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1902 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1902 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1902 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1903 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1903 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-1903 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-900 INJECTION 500 mg INTRAVENOUS ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-901 INJECTION 100 mg INTRAVENOUS ANDA 21 sections
PROCAINAMIDE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1334 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 13 sections
PROCAINAMIDE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1334 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 13 sections
PROCAINAMIDE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1392 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 13 sections
PROCAINAMIDE HCI HUMAN PRESCRIPTION DRUG LABEL 1 51662-1392 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 13 sections
PROCAINAMIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1630 INJECTION 100 mg INTRAVENOUS ANDA 13 sections
PROCAINAMIDE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-106 INJECTION, SOLUTION 500 mg INTRAMUSCULAR ANDA 12 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7115 INJECTION 1000 mg INTRAVENOUS ANDA 21 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7170 INJECTION 1000 mg INTRAVENOUS ANDA 22 sections
Procainamide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 76329-3399 INJECTION 100 mg INTRAMUSCULAR ANDA 21 sections